ZFP57 suppress proliferation of breast cancer cells through down-regulation of MEST-mediated Wnt/β-catenin signalling pathway.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Pub. Group
    • Subject Terms:
      Breast Neoplasms/*genetics ; Proteins/*metabolism ; Repressor Proteins/*metabolism ; Wnt Signaling Pathway/*genetics; Animals ; Breast Neoplasms/metabolism ; Cell Proliferation ; Cell Transformation, Neoplastic/genetics ; DNA Methylation ; Down-Regulation/genetics ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; MCF-7 Cells ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/genetics ; Promoter Regions, Genetic ; Proteins/genetics ; Repressor Proteins/genetics ; beta Catenin/metabolism
    • Abstract:
      Activation of oncogenes by promoter hypomethylation plays an important role in tumorigenesis. Zinc finger protein 57 (ZFP57), a member of KRAB-ZFPs, could maintain DNA methylation in embryonic stem cells (ESCs), although its role and underlying mechanisms in breast cancer are not well understood. In this study, we found that ZFP57 had low expression in breast cancer, and overexpression of ZFP57 could inhibit the proliferation of breast cancer cells by inhibiting the Wnt/β-catenin pathway. MEST was validated as the direct target gene of ZFP57 and MEST may be down-regulated by ZFP57 through conserving DNA methylation. Furthermore, overexpression of MEST could restore the tumour-suppressed and the Wnt/β-catenin pathway inactivated effects of ZFP57. ZFP57-MEST and the Wnt/β-catenin pathway axis are involved in breast tumorigenesis, which may represent a potential diagnostic biomarker, and provide a new insight into a novel therapeutic strategy for breast cancer patients.
    • References:
      Science. 2005 Mar 25;307(5717):1976-8. (PMID: 15731405)
      Cell. 2005 Sep 23;122(6):947-56. (PMID: 16153702)
      Proc Natl Acad Sci U S A. 2010 Jan 26;107 Suppl 1:1757-64. (PMID: 20080672)
      Cell. 1999 Aug 6;98(3):295-303. (PMID: 10458605)
      Nature. 1996 Jul 18;382(6588):225-30. (PMID: 8717036)
      Int J Oncol. 2017 Sep;51(3):801-811. (PMID: 28677721)
      Nat Genet. 2006 Apr;38(4):431-40. (PMID: 16518401)
      Biochem Biophys Res Commun. 2005 May 27;331(1):23-30. (PMID: 15845352)
      Nat Rev Genet. 2013 Mar;14(3):204-20. (PMID: 23400093)
      Cancer Res. 2014 Apr 15;74(8):2160-70. (PMID: 24737128)
      Genome Med. 2012 Mar 27;4(3):24. (PMID: 22453031)
      Cell. 2006 Nov 3;127(3):469-80. (PMID: 17081971)
      Semin Cancer Biol. 2014 Aug;27:20-9. (PMID: 24820952)
      Lancet Oncol. 2014 Apr;15(5):489-538. (PMID: 24731404)
      Genome Res. 2006 May;16(5):669-77. (PMID: 16606702)
      PLoS One. 2015 Jun 22;10(6):e0130436. (PMID: 26098312)
      Dev Cell. 2009 Jul;17(1):9-26. (PMID: 19619488)
      Cancer Res. 2001 Feb 1;61(3):1214-9. (PMID: 11221853)
      Endocr Rev. 2007 Feb;28(1):20-47. (PMID: 16931767)
      PLoS One. 2014 Oct 31;9(10):e110990. (PMID: 25360542)
      Nature. 2004 Nov 18;432(7015):324-31. (PMID: 15549094)
      Cancer Res. 1999 Nov 1;59(21):5449-51. (PMID: 10554015)
      Nature. 1981 Jul 9;292(5819):154-6. (PMID: 7242681)
      Mol Cell. 2011 Nov 4;44(3):361-72. (PMID: 22055183)
      Nature. 2000 Sep 28;407(6803):530-5. (PMID: 11029007)
      Genes Dev. 1998 Jul 1;12(13):2048-60. (PMID: 9649508)
      Cell. 2012 Dec 21;151(7):1457-73. (PMID: 23245941)
      Mutat Res. 2012 Oct-Dec;751(2):304-25. (PMID: 22698615)
      Nucleic Acids Res. 2016 Feb 18;44(3):1118-32. (PMID: 26481358)
      Epigenomics. 2009 Dec;1(2):239-59. (PMID: 20495664)
      Nat Med. 2004 Jan;10(1):55-63. (PMID: 14702635)
      Nat Cell Biol. 2011 Jun 19;13(7):753-61. (PMID: 21685890)
      Development. 2007 Feb;134(4):635-46. (PMID: 17215298)
      Nat Rev Cancer. 2004 Feb;4(2):97-105. (PMID: 14964307)
      J Biol Chem. 2012 Jan 13;287(3):2107-18. (PMID: 22144682)
      Dev Cell. 2008 Oct;15(4):547-57. (PMID: 18854139)
      Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
      Proc Natl Acad Sci U S A. 1981 Dec;78(12):7634-8. (PMID: 6950406)
      Cell Death Dis. 2018 May 14;9(5):573. (PMID: 29760376)
      J Biol Chem. 1994 Mar 4;269(9):6900-7. (PMID: 8120052)
      J Pathol. 2016 Sep;240(1):72-83. (PMID: 27265324)
      Science. 2004 Mar 5;303(5663):1483-7. (PMID: 15001769)
      J Biol Chem. 2004 Jun 11;279(24):25653-64. (PMID: 15070898)
      Int J Obes (Lond). 2015 Dec;39(12):1733-41. (PMID: 26119994)
      J Biomed Sci. 2014 Oct 07;21:97. (PMID: 25287362)
    • Accession Number:
      0 (CTNNB1 protein, human)
      0 (MicroRNAs)
      0 (Proteins)
      0 (Repressor Proteins)
      0 (ZFP57 protein, human)
      0 (beta Catenin)
      0 (mesoderm specific transcript protein)
    • Publication Date:
      Date Created: 20190222 Date Completed: 20200420 Latest Revision: 20210208
    • Publication Date:
      20240829
    • Accession Number:
      PMC6382817
    • Accession Number:
      10.1038/s41419-019-1335-5
    • Accession Number:
      30787268